Funding news
Alchemab Therapeutics Ltd logo

Alchemab Therapeutics Ltd Raises $3

Recently funded · $315.0M Series aHospitals and Health CareGBView source

Get the full Alchemab Therapeutics Ltd company profile

Access contacts, investors, buying signals & more

Open in Dashboard

The quest to unlock the protective power of patient antibodies just got a $315.0M injection. Alchemab Therapeutics Ltd, which aims to keep people free of hard-to-treat diseases, has closed its Series A funding round.

The company is developing a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first methodology, employing three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Its engine is enabled through collaborations with patient representative groups and biobanks around the world, furthering its understanding of disease.

Other United Kingdom companies recently funded

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
GRAIL logo

GRAIL

United States

$7.1B
4
Illumina logo

Illumina

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Series a rounds

Companies that recently closed a Series a round.

#CompanyAmount
1
BioTrace Medical Inc. logo

BioTrace Medical Inc.

United States

$8.5M
2
Green Hub logo

Green Hub

France

$12.8M
3
Autofleet logo

Autofleet

Israel

$9.6M
4
Airflow Systems, Inc logo

Airflow Systems, Inc

United States

$17.0M
5
Finflex logo

Finflex

$8.5M